Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

作者
Thomas DeLeon,Daniel Almquist,Benjamin R. Kipp,Blake Langlais,Aaron R. Mangold,Jennifer L. Winters,Heidi Kosiorek,Richard W. Joseph,Roxana Dronca,Matthew S. Block,Robert R. McWilliams,Lisa A. Kottschade,Kandelaria M. Rumilla,Jesse S. Voss,­Mahesh Seetharam,Aleksandar Sekulić,Svetomir N. Markovic,Alan H. Bryce
出处
期刊:PLOS ONE [Public Library of Science]
卷期号:15 (3): e0230306-e0230306 被引量:31
标识
DOI:10.1371/journal.pone.0230306
摘要

BACKGROUND: CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. METHODS: All patients with cutaneous melanoma or melanoma of unknown primary who received checkpoint inhibitor therapy and underwent genomic profiling with the 50-gene Mayo Clinic solid tumor targeted cancer gene panel were included. Patients were stratified according to the presence or absence of mutations in BRAF, NRAS, CDKN2A, and TP53. Patients without mutations in any of these genes were termed quadruple wild type (QuadWT). Clinical outcomes including median time to progression (TTP), median overall survival (OS), 6-month and 12-month OS, 6-month and 12-month without progression, ORR and disease control rate (DCR) were analyzed according to the mutational status of CDKN2A, TP53 and QuadWT. RESULTS: A total of 102 patients were included in this study of which 14 had mutations of CDKN2A (CDKN2Amut), 21 had TP53 mutations (TP53mut), and 12 were QuadWT. TP53mut, CDKN2Amut and QuadWT mutational status did not impact clinical outcomes including median TTP, median OS, 6-month and 12-month OS, 6-month and 12-month without progression, ORR and DCR. There was a trend towards improved median TTP and DCR in CDKN2Amut cohort and a trend towards worsened median TTP in the QuadWT cohort. CONCLUSION: Cell cycle regulators such as TP53 and CDKN2A do not appear to significantly alter clinical outcomes when immune checkpoint inhibitors are used.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
likang发布了新的文献求助10
刚刚
LIN完成签到,获得积分10
刚刚
伯赏迎松完成签到,获得积分10
刚刚
大个的应助被zkl采纳,获得10
1秒前
隐形曼青的应助被开心德地采纳,获得10
1秒前
1秒前
wenting完成签到,获得积分10
1秒前
奋斗断秋发布了新的文献求助10
1秒前
xxxxxxh发布了新的文献求助10
2秒前
阳克斯韦完成签到 ,获得积分10
2秒前
shenkekeshen的应助被星星采纳,获得10
2秒前
2秒前
2秒前
3秒前
8R60d8的应助被Spring采纳,获得20
4秒前
4秒前
闪闪映天发布了新的文献求助30
5秒前
顺利毕业呀完成签到,获得积分10
6秒前
6秒前
明天完成签到,获得积分10
6秒前
7秒前
7秒前
molihuakai的应助被个性向卉采纳,获得10
7秒前
jwin的应助被隐形松采纳,获得10
7秒前
Wenyilong发布了新的文献求助10
7秒前
8秒前
外向的吐司完成签到,获得积分10
8秒前
LJH发布了新的文献求助10
8秒前
8秒前
12发布了新的文献求助10
9秒前
9秒前
xxxxxxh完成签到,获得积分20
9秒前
深情安青的应助被常富育采纳,获得10
10秒前
Eng完成签到,获得积分10
10秒前
10秒前
LJH发布了新的文献求助10
10秒前
10秒前
yishu发布了新的文献求助20
11秒前
食物者发布了新的文献求助10
11秒前
慕青的应助被开心德地采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189137
求助须知:如何正确求助?哪些是违规求助? 9576601
关于积分的说明 21848766
捐赠科研通 7787145
什么是DOI,文献DOI怎么找? 3435490
关于科研通互助平台的介绍 2559732
邀请新用户注册赠送积分活动 2482462